An experimental study to evaluate safety/toxicity of intravitreal natalizumab
Indian J Ophthalmol
;
2018 Oct; 66(10): 1441-1445
Artículo
| IMSEAR
| ID: sea-196914
ABSTRACT
Purpose:
The purpose of this prospective experimental study was to evaluate the safety/toxicity of ?4?1 integrin blockade in rabbit retina using its monoclonal antibody (Natalizumab).Methods:
Twelve New Zealand albino rabbits were divided into three groups (n = 4). Unilateral intravitreal injections of three different concentrations of natalizumab were performed in every rabbit of each group (Group A 0.625 mg, Group B 1.25 mg, and Group C 2.5 mg). Baseline electroretinogram (ERG) and fundus photography were performed prior to injection. At days 1, 7, and 21 postinjection, ERG and fundus photography of each eye were performed. At last follow-up, Group C animals with highest drug concentration were sacrificed and the enucleated eyes were evaluated for retinal toxicity using transmission electron microscopy (TEM).Results:
No difference in ERG responses was observed in eyes injected with low and intermediate concentration of natalizumab between day 0 and day 21. Furthermore, rabbits injected intravitreally with highest dose showed reduction in amplitude of “a” wave (P = 0.0017) and a reduction in amplitude of “b” wave of ERG at day 21 (P = 0.0117). TEM revealed changes in the outer plexiform layer and inner nuclear layer, suggestive of toxicity primarily to the photoreceptor synaptic terminals and bipolar cells.Conclusion:
Low-dose (0.625 mg) and intermediate-dose (1.25 mg) intravitreal injection of natalizumab appears safe for rabbit retina. However, functional and anatomical changes were observed in rabbit retina following a high-dose (2.5 mg) intravitreal injection of a monoclonal antibody blocking ?4?1 integrin.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Revista:
Indian J Ophthalmol
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS